Effects of vagal nerve stimulation on pain frequency and intensity in chronic migraine in adults: A randomized controlled trial
Abstract
To determine the effects of noninvasive vagal nerve stimulation (nVNS) on the frequency, intensity, impact, and quality of life in individuals with chronic migraine. The randomized controlled trial (RCT) was conducted over 128 participants, randomly assigned to either the experimental or control group. The experimental group received nVNS, while the control group underwent sham interventions along with the prescribed medications. Data collection involved the pre and post-use of a structured headache diary, a numerical pain scale (NPS), the multidimensional pain inventory, and migraine-specific quality of life (MS-QoL) questionnaires. The experimental group's MS-QoL scores significantly improved, with a mean rank of 94.59, and p value <0.001. Similarly, the NPS scores showed that the experimental group's pain levels were considerably lower, with a mean rank of 36.77 and p value <0.001. The MPI scores highlighted a substantial reduction in pain-related interference and behaviors within the experimental group, with p value = 0.035. In terms of headache severity, the structured headache diary revealed that the experimental group experienced fewer severe headaches, with only 16 instances (15.6%), and an increase in moderate headaches to 51 instances (51.6%). The study indicates that nVNS significantly enhanced quality of life and reduced pain intensity, frequency, and impact among chronic migraine patients over 4 weeks of active stimulation.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 128 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.